Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Corona RemediesNSE:CORONA +0.37%18 ROA % is 15.05% as of Mar. 2026, which is 4% below its 10-year median of 15.63. GuruFocus rates NSE:CORONA with a GF Score™ of 18/100. The stock has 3 warning signs investors should review. Among 1,009 Drug Manufacturers companies, Corona Remedies ranks better than 89.1% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Corona Remedies's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹1,813 Mil.
Corona Remedies's average Total Assets over the quarter that ended in Mar. 2026 was ₹12,051 Mil. Therefore, Corona Remedies's annualized ROA % for the quarter that ended in Mar. 2026 was 15.05%.
The historical rank and industry rank for Corona Remedies's ROA % or its related term are showing as below:
NSE:CORONA'
s ROA % Range Over the Past 10 Years
Min: 12.66 Med: 15.63 Max: 17.34
Current: 12.66
During the past 4 years, Corona Remedies's highest ROA % was 17.34%. The lowest was 12.66%. And the median was 15.63%.
NSE:CORONA's ROA % is ranked better than 89.1% of 1009
companies
in the Drug Manufacturers industry
Industry Median: 2.72
vs NSE:CORONA: 12.66
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Corona Remedies ROA % Related Terms
Corona Remedies ROA % Historical Data
* Premium members only.
The historical data trend for Corona Remedies's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Corona Remedies's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corona Remedies ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Corona Remedies's ROA % distribution charts can be found below:
* The bar in red indicates where Corona Remedies's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Corona Remedies (NSE:CORONA) has a ROA % of 15.05% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Corona Remedies and its competitors. This is near median its historical median of 15.63. Over the past decade, Corona Remedies' ROA % has ranged from 12.66 to 17.34. According to the industry distribution chart, Corona Remedies ranks #110 out of 1009 companies in the Drug Manufacturers industry, placing it in the top 10.9%.
Is Corona Remedies' ROA % too high?
Corona Remedies' current ROA % of 15.05% is near median its 10-year median of 15.63. Over the past 10 years, this metric has ranged from a low of 12.66 to a high of 17.34. The Drug Manufacturers industry median ROA % is 2.72. Corona Remedies' value of 15.05% is 453.3% above this industry median. Based on the distribution chart, Corona Remedies ranks #110 out of 1009 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Corona Remedies has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Corona Remedies' ROA % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Corona Remedies ranks #110 out of 1009 companies for ROA %. This places Corona Remedies in the top 11% of its industry — outperforming the majority of peers. The industry median ROA % is 2.72. Corona Remedies' value of 15.05% is 453.3% above this benchmark. Historically, Corona Remedies' own ROA % has ranged from 12.66 to 17.34 over the past decade. While the company's 10-year median is 15.63 vs. the industry median of 2.72, Corona Remedies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.72, based on 1,009 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Corona Remedies's current ROA % of 15.05% is 453.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Corona Remedies and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corona Remedies's current ROA % is 15.05%, which is near median its own 10-year median of 15.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corona Remedies stock overvalued right now?
Corona Remedies (NSE:CORONA) has a current ROA % of 15.05%. The current ROA % is 15.05%, which is near median its 10-year median of 15.63 and 453.3% above the Drug Manufacturers industry median of 2.72. Corona Remedies' overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Corona Remedies (NSE:CORONA), the current ROA % is 15.05% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Corona Remedies Ltd is mainly engaged in the business of manufacturing, trading and marketing of Pharmaceutical products. It is engaged in developing, manufacturing and marketing products in women's healthcare, cardio-diabetes, pain management, urology and other segments, such as Vitamin Minerals and Nutrients(VMN), gastrointestinal and respiratory therapies. The company's brands are B-29, myoril, Tricium, Cortel, and Obimet. The Company has only one reportable business segment i.e. Pharmaceuticals. The company has presence in India as well as Outside India. The company generates majority of revenue from India.
18GF Score
Get the complete analysis for NSE:CORONA
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CORONA has been successfully added to your 
